Funding Details
- Awarder
- Inbox
- Date Award
- April 03, 2025
- Vertical
- Biotherapeutics
- Funding URL
- View Funding Page
Company Info
- Traction
- NRTX-1001 has been well-tolerated and has demonstrated substantial and durable seizure reduction in ongoing Phase 1/2 trials.
- Founders
- Cory R. Nicholas, Ph.D.
- Company Description
- Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
- Market
- Regenerative cell therapies for neurological disorders
- Location
-
South San Francisco,
California,
United States
- Coinvestors
- Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, Spur Capital Partners
Links